FusionPharm Statistics
Total Valuation
FusionPharm has a market cap or net worth of 1,259.
| Market Cap | 1,259 |
| Enterprise Value | n/a |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
FusionPharm has 12.59 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 12.59M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +4.39% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 0.02% |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.00 |
| PB Ratio | -0.01 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.73
| Current Ratio | 0.73 |
| Quick Ratio | 0.03 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.78 |
| Interest Coverage | -1,821.37 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -137.69% |
| Return on Invested Capital (ROIC) | -212.18% |
| Return on Capital Employed (ROCE) | -325.22% |
| Revenue Per Employee | 65,739 |
| Profits Per Employee | -72,786 |
| Employee Count | 5 |
| Asset Turnover | 1.99 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | -20.94 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 41.81 |
| Average Volume (20 Days) | 503 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.00 |
Income Statement
In the last 12 months, FusionPharm had revenue of 328,695 and -363,930 in losses. Loss per share was -0.15.
| Revenue | 328,695 |
| Gross Profit | 67,006 |
| Operating Income | -364,273 |
| Pretax Income | -363,930 |
| Net Income | -363,930 |
| EBITDA | n/a |
| EBIT | -364,273 |
| Loss Per Share | -0.15 |
Balance Sheet
The company has 1,450 in cash and 295,702 in debt, giving a net cash position of -294,252 or -0.02 per share.
| Cash & Cash Equivalents | 1,450 |
| Total Debt | 295,702 |
| Net Cash | -294,252 |
| Net Cash Per Share | -0.02 |
| Equity (Book Value) | -157,488 |
| Book Value Per Share | -0.07 |
| Working Capital | -11,680 |
Cash Flow
In the last 12 months, operating cash flow was -286,511 and capital expenditures -93,883, giving a free cash flow of -380,394.
| Operating Cash Flow | -286,511 |
| Capital Expenditures | -93,883 |
| Free Cash Flow | -380,394 |
| FCF Per Share | -0.03 |
Margins
Gross margin is 20.39%, with operating and profit margins of -110.82% and -110.72%.
| Gross Margin | 20.39% |
| Operating Margin | -110.82% |
| Pretax Margin | -110.72% |
| Profit Margin | -110.72% |
| EBITDA Margin | n/a |
| EBIT Margin | -110.82% |
| FCF Margin | n/a |
Dividends & Yields
FusionPharm does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -28,906.27% |
| FCF Yield | -30,213.98% |
Stock Splits
The last stock split was on March 1, 2011. It was a reverse split with a ratio of 0.005.
| Last Split Date | Mar 1, 2011 |
| Split Type | Reverse |
| Split Ratio | 0.005 |
Scores
FusionPharm has an Altman Z-Score of -6.94. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.94 |
| Piotroski F-Score | n/a |